Lilly bets $8bn on genomic approach to cancer 07-Jan-2019 By Ben Hargreaves Eli Lilly will acquire Loxo for $8bn to gain access to treatments that target cancers dependent on single gene abnormalities.
China boasts second domestically developed PD-1 approval 04-Jan-2019 By Ben Hargreaves Eli Lilly and Innovent announced that their jointly developed anti-PD-1 drug gained approval in China, becoming the second domestically produced treatment of this type.